Format

Send to

Choose Destination
Ocul Immunol Inflamm. 2013 Apr;21(2):160-2. doi: 10.3109/09273948.2012.741744. Epub 2012 Dec 19.

Behçet disease-associated uveitis successfully treated with golimumab.

Author information

1
Ophthalmology Department, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain.

Abstract

Over the past decade, the off-label use of biologic agents such as TNF-α antagonists, including infliximab and adalimumab, has improved the treatment armamentarium for refractory immune-mediated uveitis, with particular success in Behçet disease-associated uveitis. Golimumab is a novel fully human anti-TNF-α monoclonal antibody that has been approved for the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, with very promising results. Herein, the authors present the use of GLM in a case of Behçet uveitis refractory to other TNF-α blockers. There are only two reports in the literature about the use of GLM in uveitis, describing four patients with JIA-associated uveitis and a case of idiopathic retinal vasculitis. To the authors' knowledge, this is the first report about the use of GLM in Behçet uveitis.

PMID:
23252659
DOI:
10.3109/09273948.2012.741744
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center